

# NSIDES: DRUG EFFECT DISCOVERY USING THE FDA ADVERSE REPORTING SYSTEM

RAMI S VANGURI

*Department of Biomedical Informatics, Columbia University,  
New York, NY 10032 USA  
E-mail: r.vanguri@columbia.edu*

JOSEPH D ROMANO

*Department of Biomedical Informatics, Columbia University,  
New York, NY 10032 USA  
E-mail: jdr2160@columbia.edu*

TAL LORBERBAUM

*Department of Biomedical Informatics, Columbia University,  
New York, NY 10032 USA  
E-mail: tal.lorberbaum@columbia.edu*

VICTOR NWANKWO

*Department of Biomedical Informatics, Columbia University,  
New York, NY 10032 USA  
E-mail: vtn2106@columbia.edu*

CHOONHAN YOUN

*San Diego Supercomputer Center, University of California, San Diego,  
La Jolla, CA 92093 USA  
E-mail: cyoun@sdsc.edu*

NICHOLAS P TATONETTI

*Department of Biomedical Informatics, Columbia University,  
New York, NY 10032 USA  
E-mail: nick.tatonetti@columbia.edu*

Adverse drug events are a leading cause of morbidity and mortality around the world. Regulatory agencies, such as the Food and Drug Administration (FDA), maintain large collections of adverse event reports, providing an opportunity to retrospectively study drug and drug combination effects. We mined the FDA Adverse Event Reporting System (FAERS) for significant adverse reactions and developed a database of drug effects, known as nSides. FAERS contains millions of reports covering thousands of drugs and thousands of effects, requiring the computing of approximately X billion models. In order to calculate side effect significances for all drug combinations reported in FAERS, we present a distributed, on-demand computational architecture.

## 1. Introduction

Spontaneous reporting systems such as the FDA Adverse Event Reporting System (FAERS) are important resources for detecting drug adverse events after a drug is approved (pharmacovigilance). However, pharmacovigilance algorithms often lead to many false positive and false negative findings due to issues of confounding, and detection of drug-drug interactions is an even greater challenge. We previously developed databases for off-label drug effects (OFFSIDES) and drug interactions (TWO SIDES) that account for these limitations using a novel Statistical Correction for Uncharacterized Bias (SCRUB).<sup>1</sup> We re-mined FAERS with an updated algorithm to populate a new version of the databases, known as nSides. nSides also contains a public web gateway (<http://nsides.io/>) accessible to researchers, clinicians and patients alike.

## 2. Data Sources

There are several data sources which are involved in nSides. We use a curated version of the FDA Adverse Event Reporting System (FAERS) known as Adverse Event Open Learning through Universal Standardization (AEOLUS).<sup>2</sup> AEOLUS aims to clean and normalize the data by removing duplicate cases. This is done by applying standardized vocabularies in the form of RxNorm to map drug names and SNOMED-CT to map outcomes. The AEOLUS dataset is publicly available.

## 3. Methods

### 3.1. Algorithm

The algorithm used to develop the databases used for nSides is an updated version of the one used to populate the OFFSIDES and TWO SIDES databases. These databases contain side effect significances calculated using raw FAERS data.<sup>1</sup> Generally, a standard signal detection algorithm involves conducting a disproportionality analysis by comparing the observed reporting frequency of a drug and outcome to the expected reporting frequency of all other drugs and the outcome. The metric is known as a Proportional Reporting Ratio (PRR). If the outcome occurred by chance, the frequencies will be equal and the PRR will be one. If the PRR is much larger than one, the null hypothesis is rejected. To reduce sampling variance and selection bias, propensity score matching is implemented to form the groups used in the disproportionality analysis. This procedure, known as SCRUB, matches cases and controls between patients exposed and not exposed to a particular drug (OFFSIDES) or two drugs (TWO SIDES) to mitigate confounding biases. Once cases and controls are matched, the PRR for various side effects are calculated.

There are several key differences between the OFFSIDES and TWO SIDES databases and nSides. The updated algorithm uses a deep learning model instead of logistic regression to calculate propensity scores to match cases and controls. As a result, the computational power required to populate nSides is much greater. Additionally, nSides is not designed to be limited to effects of single and interactions of 2 drugs.

tensorflow-gpu

### 3.2. Computational Challenge

Populating the nSides database requires the SCRUB procedure to be run for each drug or combination of drugs individually to identify appropriate cases and controls. Once cases and controls are identified, PRR values need to be calculated over a range of side effects. Since the AEOLUS dataset contains  $\approx 4,000$  drugs,  $\approx 5,000,000$  reports, and  $\approx 8,000$  effects to analyze, a computational challenge emerges.

The nSides database is initially populated with single drug effects. To do this, a deep neural network model is generated for each unique  $\approx 4,500$  drugs in the AEOLUS dataset. The models are generated using the TensorFlow machine learning library. Because the computation involved in deep neural network model generation is more intensive than the logistic regression models used for the creation of OFFSIDES and TWOSIDES, a more complicated computational infrastructure is used.

### 3.3. Computational Structure

Generating a model for an individual drug involves the following:

- (1) Dimensional reduction of the complete AEOLUS dataset: only consider co-reported drugs that appear in at least 1 report
- (2) Separate exposed and non-exposed reports
- (3) Generate deep learning models
- (4) Use resulting scores to perform propensity score matching
- (5) Evaluate side effect PRR values
- (6) Populate nSides database

## References

1. N. P. Tatonetti, P. P. Ye, R. Daneshjou and R. B. Altman, *Science Translational Medicine* **4**, 125ra31 (2012).
2. J. M. Banda, L. Evans, R. S. Vanguri, N. P. Tatonetti, P. B. Ryan and N. H. Shah, *Scientific data* **3** (2016).